Press release
RxReview LLC Announces Epi-Help Patient Assistance Program
RxReview LLC Announces Epi-Help Patient Assistance Program for EpiPen
The Epi-Help program aggregates both governmental and industry charity programs to enable patients to fill their EpiPen/EpiPen Jr. prescription at an affordable price. “Traditionally, RxReview has provided hospitals with pharmaceutical replenishment services for those medications dispensed through charity care programs. With the price of the EpiPen increasing by 300%, we have re-tasked our client services group to assist patients in filling their EpiPen prescription at an affordable price. Although the Epi-Help program provides assistance to all, it is particularly helpful to those that have no insurance,” said Jerry Wanio, CEO of RxReview LLC.
About RxReview LLC
RxReview LLC is a national leader and founding pioneer in the processing of pharmaceutical replenishment for hospitals utilizing charity care programs. Additionally, they remain a leader in compliance with both manufacturer and governmental regulations. With the rising cost of both insurance and prescription drugs, RxReview has expanded, its offerings to include prescription cost avoidance programs as well as Patient Access services.
RxReview Services LLC
300 Eagle Rock Avenue
3rd Floor
East Hanover, New Jersey 08936
Tel: 973-893-1119
Communications: Thomas Clark
Info@RxReviewLLC.com
RxSupplementLLC.Com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RxReview LLC Announces Epi-Help Patient Assistance Program here
News-ID: 360965 • Views: …
More Releases for EpiPen
Epinephrine Market Five Years Forecast Skeleton With Key Companies Pfizer, Teva …
The global epinephrine market size was valued at US$ 2,040 million in 2017, and is expected to exhibit a CAGR of 11.0% over the forecast period (2018 – 2026).
Launch of cost effective generic epinephrine products by the manufacturers is majorly attributed to the high price of EpiPen developed by Mylan NV. The price hike was not accepted by the public, as the drug price increased to more than 400% over…
Auto-Injectors Market Progresses for Huge Growth of US$ 6,800 Mn by 2026 | Mylan …
Anaphylactic shock is the most common chronic disease in Europe and North America region. Allergy UK says, approximately 20% of patients struggle with anaphylactic reaction in Europe. Anaphylactic shock requires adrenaline auto injector devices to be treated. Adrenaline auto injectors are sold under various brands, such as Emerade, Epipen and Jext in the UK. The global auto injectors market was valued at US$ US$ 1,700 Mn, in terms of value,…
Autoinjectors Market Size, Share, Growth, Trends, And Forecasts (2018–2023)
Recent Developments
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Offer a growing portfolio of more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies. Mylan N.V. has announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector. EpiPen® and EpiPen Jr® Auto-Injectors are used for the emergency treatment of life-threatening allergic reactions. The approved generic will be identical to the branded product,…
Auto-injectors Market Insights, Trends, Outlook, and Opportunity Analysis, 2018- …
Auto-injector is a needle based medical device which is used for the administration of a fixed dose of a particular drug. It can be used for self-administration by the patients or untrained person, as it is easy to handle. Furthermore, auto-injector is significantly used for various mild and severe allergic reactions. If allergic reaction are not cured, then it can even lead to life-threatening condition such as anaphylaxis. Allergy symptoms…
Auto-Injectors Market to Grow at a CAGR of 15.1% by 2026
Prefilled auto-injectors segment anticipated to contribute to the highest growth opportunity due to growing demand for intramuscular drug delivery in the global auto-injectors market
Auto-injectors are pen like devices used to deliver a fixed dose of drug to patients and are intended for self-administration. Auto-injectors are gradually becoming the gold-standard in the treatment of various indications like anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. Most of the auto-injectors are spring loaded,…
Lone Star Script Care Has the Lowest Prices Prescriptions in America!
Recent headlines have been focusing on Mylan Pharmaceutical Company's controversy after increasing the price of the life-saving therapy, EpiPen. The therapy went from $100 a few years ago to $608 retail today.
On Thursday, August 25, 2016 the company's CEO, Heather Bresch committed to an interview on CNBC. She attempted to explain that "our health system is broken" and that the chain of intermediaries, as a result of our health system's…
